問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

黃宗楨
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

39Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃宗楨

List

43Cases

2023-07-31 - 2031-02-01

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    sotorasib (AMG 510)Pembrolizumab

Participate Sites
7Sites

Recruiting7Sites

2024-01-22 - 2027-05-27

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Condition/Disease

    Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2025-04-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

  • Condition/Disease

    Non–small cell lung cancer (NSCLC)

  • Test Drug

    Durvalumab Olomorasib Pembrolizumab

Participate Sites
18Sites

Recruiting18Sites

2022-08-12 - 2027-02-20

Phase III

Active
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    JDQ443

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated2Sites

2025-04-04 - 2029-12-07

Phase I/II

Not yet recruiting
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    LUTATHERA® (AAA601) NETSPOT® (AAA501)

Participate Sites
3Sites

Recruiting3Sites

2025-04-01 - 2033-01-20

Phase III

Not yet recruiting
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

  • Condition/Disease

    Nonsquamous non–small cell lung cancer (NSCLC)

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
9Sites

Recruiting9Sites

2022-05-10 - 2026-06-30

Phase III

Active
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)

  • Condition/Disease

    Nonsquamous Non-small Cell Lung Cancer

  • Test Drug

    注射用凍晶粉末

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2025-12-31

Phase II

Completed
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

  • Condition/Disease

    Small Cell Lung Carcinoma、 Neuroendocrine Neoplasms 、Extra-pulmonary Neuroendocrine Carcinoma

  • Test Drug

    N/A

Participate Sites
3Sites

Terminated3Sites

2025-09-01 - 2028-09-30

Phase I

Active
AN OPEN-LABEL, MULTICENTER PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Injectable solution

Participate Sites
5Sites

Recruiting5Sites

2022-05-10 - 2026-08-04

Phase III

HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Patritumab Deruxtecan (U3-1402)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB